Antiviral Research 2014-12-01

Small molecule inhibitors of Ago2 decrease Venezuelan equine encephalitis virus replication.

Cathaleen Madsen, Idris Hooper, Lindsay Lundberg, Nazly Shafagati, Alexandra Johnson, Svetlana Senina, Cynthia de la Fuente, Lisa I Hoover, Brenda L Fredricksen, Jonathan Dinman, Jonathan L Jacobs, Kylene Kehn-Hall

文献索引：Antiviral Res. 112 , 26-37, (2014)

全文：HTML全文

摘要

Venezuelan equine encephalitis virus (VEEV) is classified as a Category B Select Agent and potential bioterror weapon for its severe disease course in humans and equines and its potential for aerosol transmission. There are no current FDA licensed vaccines or specific therapies against VEEV, making identification of potential therapeutic targets a priority. With this aim, our research focuses on the interactions of VEEV with host microRNA (miRNA) machinery. miRNAs are small non-coding RNAs that act as master regulators of gene expression by downregulating or degrading messenger RNA, thus suppressing production of the resultant proteins. Recent publications implicate miRNA interactions in the pathogenesis of various viral diseases. To test the importance of miRNA processing for VEEV replication, cells deficient in Ago2, an important component of the RNA-induced silencing complex (RISC), and cells treated with known Ago2 inhibitors, notably acriflavine (ACF), were utilized. Both conditions caused decreased viral replication and capsid expression. ACF treatment promoted increased survival of neuronal cells over a non-treated, infected control and reduced viral titers of fully virulent VEEV as well as Eastern and Western Equine Encephalitis Viruses and West Nile Virus, but not Vesicular Stomatitis Virus. ACF treatment of VEEV TC-83 infected mice resulted in increased in vivo survival, but did not affect survival or viral loads when mice were challenged with fully virulent VEEV TrD. These results suggest that inhibition of Ago2 results in decreased replication of encephalitic alphaviruses in vitro and this pathway may be an avenue to explore for future therapeutic development. Copyright © 2014 Elsevier B.V. All rights reserved.